BACE inhibitors were developed to reduce amyloid production and tested in multiple large-scale trials, including early and preclinical populations. Despite a strong biological rationale, these trials were halted for lack of efficacy or adverse outcomes, leaving open questions about timing, patient selection and mechanism. Historically each trial was analyzed in isolation; by harmonizing and reanalyzing data across trials, this project enables a more complete evaluation of treatment effects in early-stage populations — to inform future prevention strategies and better trial design.

The project applies the AD Data Initiative's model of unlocking high-value datasets and enabling secure, scalable analysis through AD Workbench, where researchers run reproducible workflows without moving sensitive data.

Operating as a consortium of academic, nonprofit and industry partners, it combines previously siloed trial data to revisit questions no single study could answer — whether prior outcomes reflect true lack of efficacy or the limits of design, duration or population.